Aion Therapeutic Inc.
ANTCF
$0.00
-$0.02-90.56%
OTC PK
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 50.63% | -19.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 50.63% | -19.84% | |||
| Cost of Revenue | 48.01% | -0.28% | |||
| Gross Profit | 56.47% | -44.23% | |||
| SG&A Expenses | -39.19% | 26.91% | |||
| Depreciation & Amortization | 26.79% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.55% | 16.91% | |||
| Operating Income | 55.67% | -70.13% | |||
| Income Before Tax | 51.78% | -57.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 51.78% | -57.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.78% | -57.61% | |||
| EBIT | 55.67% | -70.13% | |||
| EBITDA | 56.53% | -71.70% | |||
| EPS Basic | 55.56% | -50.00% | |||
| Normalized Basic EPS | 50.00% | -50.00% | |||
| EPS Diluted | 55.56% | -50.00% | |||
| Normalized Diluted EPS | 50.00% | -50.00% | |||
| Average Basic Shares Outstanding | 2.71% | 7.01% | |||
| Average Diluted Shares Outstanding | 2.71% | 7.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||